Novo Nordisk Pharmatech has announced it will be attending the annual Cell Line Development and Engineering Asia at the Hilton Shanghai Hongqiao.

Taking place from 15 May to 18 May, Novo Nordisk Pharmatech invite you visit its stall at booth #12 to discover more about recombinant insulin for innovative biologics.

The event is part of the Biopharma Development and Production week and co-located with Biosimilars and Biomanufacturing to increase networking opportunities for all within the biopharmaceutical value chain.

Novo Nordisk Pharmatech is one of the leading worldwide suppliers of recombinant insulin. Its products are key components in serum-free growth media for mammalian cells and approved by regulatory bodies worldwide, including the Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The products are also manufactured to current good manufacturing practice (cGMP) standards, guaranteeing:

  • Global regulatory compliance
  • Consistent high quality
  • Extensive regulatory documentation
  • Continuous availability
  • Secure global supply chain
  • High levels of service and support

Novo Nordisk delivers a proven record of product purity, reliability, and consistency. It can even tailor quality products for future therapies.